Association of Beta-Blocker Therapy at Discharge With Clinical Outcomes in Patients With Actue Coronary Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

582 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-03-02

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Limited data are available on the efficacy of beta-blocker therapy for secondary prevention in Actue Coronary Syndrome(ACS) patients. This study sought to investigate the association of beta-blocker therapy at discharge with clinical outcomes in patients with ACS after percutaneous coronary intervention (PCI).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Real World Assessment of Effects of Beta-blockers on Patients With Acute Coronary Syndrome

NCT03669991

Acute Coronary Syndrome

UNKNOWN

Real-world Use and Prognosis of Beta Blocker in Patients With Acute Coronary Syndrome in the Central China

NCT03116854

Acute Coronary Syndrome

COMPLETED

The Contemporary Role of Beta Blockers in Patients With Acute Myocardial Infarction

NCT04564365

Acute Coronary Syndrome

UNKNOWN

A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute Coronary Syndrome

NCT03413410

ACS - Acute Coronary Syndrome

UNKNOWN NA

The Effect of Beta-blocker on Chronotropic Response and Cardiorespiratory Fitness in Patients With Atrial Fibrillation

NCT05332457

Atrial Fibrillation

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommend beta-blockers for secondary prevention in patients with ACS without regard to reperfusion therapy. However, evidence supporting this recommendation originated from studies conducted before the introduction of reperfusion therapy or studies in patients treated with fibrinolysis. In the present era of PCI, there are no prospective randomized studies looking at the effects of long-term beta-blocker therapy on clinical outcomes in ACS patients. Moreover, results from registry data and post-hoc analysis on beta-blocker therapy in patients undergoing PCI are inconsistent.

In particular, the beneficial effect of long-term beta-blocker therapy has not been well established in patients with relatively low risk, such as preserved left ventricular systolic function or single-vessel disease. Therefore, we investigated the association of beta-blocker therapy at discharge with clinical outcomes in ACS patients after PCI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Actue Coronary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. consecutive patients 18 years of age or older;
2. patients diagnosed as ACS(including STEMI、NSTEMI and UA) by doctor at discharge;
3. patients undergoing primary PCI.